ccdc43 Antibody

What is CCDC43 and what are its key characteristics?

CCDC43 is a protein belonging to the coiled-coil domain-containing family. In humans, the canonical protein has the following properties:

• Length: 224 amino acid residues

• Molecular mass: 25.2 kDa

• Number of isoforms: Up to 2 different isoforms have been reported

• Expression pattern: Widely expressed across many tissue types

• Conservation: CCDC43 gene orthologs have been identified in multiple species including mouse, rat, bovine, frog, zebrafish, chimpanzee and chicken

The protein is also known by the synonym "coiled-coil domain-containing protein 43" and has gained significant research interest due to its emerging role in cancer progression.

What are the primary applications of CCDC43 antibodies in research?

CCDC43 antibodies are versatile tools employed in multiple experimental procedures with specific applications including:

The choice of application should be guided by the specific research question and experimental design, with appropriate controls implemented for each technique .

How can I validate the specificity of a CCDC43 antibody?

Validating antibody specificity is critical for ensuring reliable experimental results. For CCDC43 antibodies, consider the following validation methodology:

• Genetic validation:

  • Use CCDC43 knockdown (siRNA) or knockout cells as negative controls

  • Compare signal in cells with CCDC43 overexpression versus vector control

• Molecular weight verification:

  • Confirm that the detected band corresponds to the expected molecular weight (~25.2 kDa)

  • Be aware that post-translational modifications may alter apparent molecular weight

• Cross-validation:

  • Compare results from multiple antibodies targeting different epitopes of CCDC43

  • Correlate protein detection with mRNA expression data

• Species cross-reactivity testing:

  • If using the antibody across species, verify specificity in each target organism

  • Note that antibodies may have different detection efficiencies across species

How should I design experiments to study CCDC43's role in cell proliferation?

When investigating CCDC43's impact on cell proliferation, consider this comprehensive experimental approach:

• Expression modulation:

  • Establish stable cell lines with CCDC43 overexpression or knockdown

  • Use inducible expression systems for temporal control

  • Confirm expression levels by Western blotting

• Proliferation assays:

  • EdU incorporation assay to measure DNA synthesis

  • Real-time cell proliferation monitoring using impedance-based systems

  • Colony formation assays for long-term growth effects

• Cell cycle analysis:

  • Flow cytometry to determine cell cycle distribution (G0/G1, S, G2/M phases)

  • Western blot analysis of cell cycle-related proteins:

    • Measure Cyclin D1, CDK4, and CDK6 (G1/S transition markers)

    • Assess Cyclin B1 (G2/M transition marker)

Research has demonstrated that CCDC43 knockdown increases the proportion of cells in G0/G1 phase while decreasing the proportion in S phase, suggesting a role in cell cycle regulation .

What methods are recommended for studying CCDC43 in cancer metastasis?

To investigate CCDC43's role in metastasis, implement a multi-level experimental approach:

• In vitro migration and invasion assays:

  • Wound healing assay to assess collective cell migration

  • Transwell invasion assay using Matrigel-coated chambers

  • Time-lapse microscopy for single-cell tracking

• EMT marker analysis:

  • Assess epithelial markers (E-cadherin, ZO-1) and mesenchymal markers (N-cadherin, Vimentin) by Western blot and immunofluorescence

  • Evaluate morphological changes (epithelial vs. mesenchymal phenotypes)

  • Analyze TGF-β pathway activation, as CCDC43 has been shown to induce EMT through this signaling mechanism

• In vivo metastasis models:

  • Orthotopic implantation models for physiologically relevant tumor microenvironment

  • Tail vein injection to assess extravasation and colonization

  • Analysis of regional lymph nodes for metastatic cells expressing CCDC43

Evidence suggests high CCDC43 expression correlates with increased migration and invasion in colorectal cancer cells, with 10/10 metastatic lymph node tissues showing elevated CCDC43 expression in clinical samples .

How does FOXK1 regulate CCDC43 expression and function?

The relationship between FOXK1 and CCDC43 represents an important regulatory axis in cancer biology:

• Transcriptional regulation:

  • FOXK1 directly binds to the CCDC43 gene promoter

  • Promoter assays have demonstrated that FOXK1 activates CCDC43 transcription

  • A positive correlation between FOXK1 and CCDC43 expression patterns has been observed in colorectal cancer cells

• Functional relationship:

  • CCDC43 is necessary for FOXK1-mediated EMT and metastasis

  • This has been demonstrated both in vitro and in vivo

  • The FOXK1-CCDC43 axis appears to be a potentially targetable pathway in cancer progression

• Experimental approaches to study this axis:

  • Chromatin Immunoprecipitation (ChIP) to confirm FOXK1 binding to the CCDC43 promoter

  • Luciferase reporter assays to quantify promoter activation

  • Co-expression analysis in clinical samples

  • Rescue experiments (CCDC43 overexpression in FOXK1-depleted cells)

What are the technical considerations for CCDC43 immunohistochemistry in clinical samples?

When performing IHC for CCDC43 in clinical specimens, researchers should consider:

• Tissue preparation:

  • Optimal fixation parameters (typically 10% neutral buffered formalin for 24-48 hours)

  • Paraffin embedding and sectioning thickness (4-5 μm recommended)

  • Antigen retrieval methods (heat-induced epitope retrieval often required)

• Staining protocol optimization:

  • Antibody dilution series to determine optimal concentration

  • Blocking procedure to minimize non-specific binding

  • Detection system selection (DAB vs. fluorescent)

  • Counterstaining approach

• Scoring and interpretation:

  • Develop a consistent scoring system (e.g., H-score, Allred score)

  • Consider both staining intensity and percentage of positive cells

  • Correlate with clinicopathological parameters and patient outcomes

• Clinical relevance:

  • CCDC43 expression has been associated with tumor progression and poor prognosis in colorectal cancer patients

  • Expression levels correlate with advanced AJCC stages (III and IV)

  • There is a relationship between primary lesion expression and regional lymph node metastasis

Why might I observe inconsistent results when detecting CCDC43?

Several factors can contribute to variability in CCDC43 detection:

• Isoform complexity:

  • Up to 2 different isoforms have been reported for CCDC43

  • Antibody epitope location may affect detection of specific isoforms

  • Consider using antibodies targeting different regions of the protein

• Technical variables:

  • Sample preparation (lysis buffers, protein denaturation conditions)

  • Transfer efficiency in Western blotting

  • Fixation methods for immunofluorescence and IHC

  • Cross-reactivity with related proteins

• Biological variability:

  • Cell type-specific expression patterns

  • Influence of cell culture conditions (confluence, serum levels)

  • Stress responses that may alter protein expression or localization

• Recommended controls:

  • Positive control (cell line known to express CCDC43, such as LoVo, DLD1, HT29, SW1116, SW480)

  • Negative control (CCDC43 knockdown cells or FHC normal colon cell line)

  • Loading controls for Western blot quantification

How can I optimize EMT studies involving CCDC43?

When investigating CCDC43's role in EMT, consider these methodological approaches:

• Morphological assessment:

  • Phase-contrast microscopy to observe epithelial vs. mesenchymal morphology

  • Documentation of cell shape changes from cobblestone-like epithelial to spindle-shaped mesenchymal phenotype

• Molecular markers analysis:

  • Western blot, qPCR, and immunofluorescence to assess:

    • Epithelial markers: E-cadherin, claudins, occludins

    • Mesenchymal markers: N-cadherin, vimentin, fibronectin

    • EMT transcription factors: Snail, Slug, ZEB1/2, Twist

• Functional assays:

  • Migration assays (wound healing, transwell)

  • Invasion assays (Matrigel-coated transwell)

  • 3D culture systems to assess morphogenesis

• Signaling pathway analysis:

  • TGF-β pathway activation (phospho-Smad2/3)

  • Additional pathways: Wnt/β-catenin, Notch, MAPK

  • Consider inhibitor studies to establish causality

Research has shown that CCDC43 induces EMT through TGF-β signaling, providing a mechanistic framework for these studies .

What emerging approaches might advance CCDC43 research beyond antibody-based methods?

Several cutting-edge techniques offer promising avenues for CCDC43 research:

• CRISPR/Cas9 genome editing:

  • Generation of CCDC43 knockout cell lines for functional studies

  • Knock-in of fluorescent tags for live-cell imaging

  • Creation of point mutations to study structural domains

• Proximity-based protein interaction studies:

  • BioID or APEX2 proximity labeling to identify interaction partners

  • FRET/BRET approaches to study dynamic protein-protein interactions

  • Split-protein complementation assays

• Single-cell analysis:

  • Single-cell RNA-seq to study expression heterogeneity

  • Mass cytometry for protein-level analysis in heterogeneous populations

  • Spatial transcriptomics to examine CCDC43 expression in tissue context

• Therapeutic targeting strategies:

  • Small molecule inhibitors of the FOXK1-CCDC43 axis

  • Peptide-based approaches targeting key interaction domains

  • Evaluation of the CCDC43 pathway as a biomarker for existing therapies

How might CCDC43 research contribute to clinical applications?

The translational potential of CCDC43 research includes:

• Prognostic biomarker development:

  • CCDC43 expression has been associated with tumor progression and poor prognosis in CRC patients

  • Standardized IHC protocols could be developed for clinical implementation

  • Multi-marker panels incorporating CCDC43 may improve prognostic accuracy

• Therapeutic targeting:

  • The FOXK1-CCDC43 axis might be explored for drug development

  • Inhibition of this pathway could potentially reduce EMT and metastasis

  • Combination approaches with standard-of-care therapies warrant investigation

• Patient stratification:

  • CCDC43 expression patterns might identify patient subgroups most likely to benefit from specific therapies

  • Integration with other molecular markers could enhance precision medicine approaches

• Monitoring treatment response:

  • Changes in CCDC43 expression or activation might serve as pharmacodynamic markers

  • Liquid biopsy approaches could potentially track CCDC43-expressing circulating tumor cells